Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Finanical ReportsHKG: 2359

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit…

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211
Clinical trial approval / initiationHKG: 0719

Xinhua Pharma Wins China Trial Approval for Dual‑Mechanism PAH Drug LXH‑1211

Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors
ADC / XDCCancer

Simcere Secures FDA Approval for ADC SIM0609 in Advanced Solid Tumors

CMS Wins NMPA Green Light for Phase‑3 Trial of MG‑K10 Anti‑IL‑4Rα in Chronic Urticaria
China Medical SystemClinical trial approval / initiation

CMS Wins NMPA Green Light for Phase‑3 Trial of MG‑K10 Anti‑IL‑4Rα in Chronic Urticaria

Eisai & Biogen Secure Leqembi China Maintenance Approval
BiogenEisai

Eisai & Biogen Secure Leqembi China Maintenance Approval

Show More